ENG and neoplasm: In 1995, CD105 was described as a receptor overexpressed in tumor vasculature [47] and, more recently, it has been shown that high CD105 expression on vessels is correlated with poor prognosis in many solid tumors, such as kidney [48], prostate [49], and ovarian cancer [50].